BCAB – bioatla, inc. (US:NASDAQ)
Stock Stats
News
BioAtla Announces Formal Process to Evaluate Strategic Options to Monetize Assets [Yahoo! Finance]
BioAtla Announces Formal Process to Evaluate Strategic Options to Monetize Assets
BioAtla (NASDAQ:BCAB) is now covered by analysts at Rodman & Renshaw. They set a "buy" rating and a $4.00 price target on the stock.
BioAtla and GATC Health to advance Oz-V in Phase III trial [Yahoo! Finance]
BioAtla and GATC Health Announce a $40 Million Special Purpose Vehicle (SPV) Transaction to Advance Ozuriftamab Vedotin (Oz-V) into a Registrational Trial for 2L+ Oropharyngeal Squamous Cell Carcinoma (OPSCC) [Yahoo! Finance]
Form 424B2 BioAtla, Inc.
Form 4 BioAtla, Inc. For: Mar 11 Filed by: SHORT JAY M PHD
Form 4 BioAtla, Inc. For: Mar 10 Filed by: Vasquez Christian
Form 4 BioAtla, Inc. For: Mar 10 Filed by: Sievers Eric
Form 424B2 BioAtla, Inc.
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.